Radhakrishnan Maha reported TRDA

Source

Document

SEC Form 4

Publisher

U.S. Securities and Exchange Commission (EDGAR)

Document ID

0002013423-26-000002

Machine-readable

Structured copy

Timestamps

Event (reported)

Jun 10, 2026

Published

Jun 12, 2026

Ingested by INSIDER

Nov 5, 03:53 UTC

Last re-read

Nov 5, 03:53 UTC

Extracted facts

Filer

Radhakrishnan Maha

Role

Director

Transaction

Grant or awardAs filed: “A”

Asset

Entrada Therapeutics, Inc. — Stock Option (Right to Buy)

Ticker

TRDA

Shares

19.0K

Price per share

$0

Execution date (reported)

Jun 10, 2026

Owned after transaction

19.0K shares

Days from execution to publication

2

What this establishes

Radhakrishnan Maha filed this Form 4 reporting a grant or award of TRDA on Jun 10, 2026. It became public on Jun 12, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

Extraction

Method

Form 4 XML

Confidence

1.00

Director

Radhakrishnan Mahacik:0002013423

Issuer

Entrada Therapeutics, Inc.cik:0001689375

Revision history · 0

No field has changed since this record was first ingested.